But Sanofi said the risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia was around two in 1,000 and these individuals recovered with treatment. Severe dengue caseOne 12-year old girl in Tarlac province, north of the Philippine capital Manila, who completed the three-dose vaccine treatment, showed symptoms of severe dengue, Health Undersecretary Gerardo Bayugo told Reuters by phone. Dengvaxia, the first approved dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales. The World Health Organisation said on Monday it hopes to review safety data this month on Sanofi's dengue vaccine which the company said was approved in 19 countries and launched in 11. Dengue is a mosquito-borne tropical disease that kills about 20,000 people a year and infects hundreds of millions.

Source: bd News24 December 05, 2017 09:11 UTC